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Patients with relapsed malignant glioma have a poor prognosis. We developed a strategy of vaccination using autologous mature
dendritic cells loaded with autologous tumour homogenate. In total, 12 patients with a median age of 36 years (range: 11–78) were
treated. All had relapsing malignant glioma. After surgery, vaccines were given at weeks 1 and 3, and later every 4 weeks. A median of
5 (range: 2–7) vaccines was given. There were no serious adverse events except in one patient with gross residual tumour prior to
vaccination, who repetitively developed vaccine-related peritumoral oedema. Minor toxicities were recorded in four out of 12
patients. In six patients with postoperative residual tumour, vaccination induced one stable disease during 8 weeks, and one partial
response. Two of six patients with complete resection are in CCR for 3 years. Tumour vaccination for patients with relapsed
malignant glioma is feasible and likely beneficial for patients with minimal residual tumour burden.
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In spite of modern oncological treatment, the prognosis of
glioblastoma multiforme (GBM) remains dismal, with a median
survival of less than 2 years (Young et al,1 9 8 1 ;S h r i e v eet al, 1999;
Wolff et al, 2000). The prognosis at time of relapse is even worse
(Finlay et al,1 9 9 5 ;N i e d e ret al, 2000; Brada et al, 2001; Tamber and
Rutka, 2003; Rich et al, 2004). However, new treatment strategies are
under development, one of them being immune therapy.
Brain tumours are considered to be located in a site of relative
immune privilege (Walker et al, 2002). Malignant gliomas have
immune suppressive characteristics locally (Black et al, 1992) and
systemically (Elliott et al, 1990). In case of vaccination, immune
responses are induced at sites remote from the tumour. Effector
cells then recirculate to mediate their antitumour effects in the
brain. The concept of tumour vaccination using dendritic cells
(DC) has been demonstrated in animal models (De Vleeschouwer
et al, in press). Phase I studies have demonstrated feasibility, safety
and bioactivity of autologous peptide-pulsed DC vaccine for
patients with malignant glioma (Yu et al, 2001). Early clinical
experiences with immunotherapy using protein-pulsed DC suggest
this to be a promising strategy for patients with recurrent
malignant glioma (Wheeler et al, 2003; Yamanaka et al, 2003; De
Vleeschouwer et al, 2004).
We summarise our experience in a group of patients with
relapsed malignant glioma, who were treated with autologous DC
loaded with proteins derived from autologous tumour homogenate.
MATERIALS AND METHODS
Patient population
All patients had a relapsing malignant glioma. Patients were
considered candidates for adjuvant vaccination if a new operation
with the intent to extensively debulk the tumour was deemed safe
by the neurosurgeon. No further restrictions were applied to
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lrecruit the patients. In this feasibility study, no patient dropped
out after reoperation. Patient characteristics are described in
Table 1. There were 12 patients (seven female and five male) with a
median age of 32 years (range: 11–78 years). Eight patients were
vaccinated at first relapse, while four patients had more than one
malignant event prior to vaccination. All patients were reoperated
upon and were off steroids and nonsteroidal anti-inflammatory
drugs at the time of vaccination. Approval by the local ethical
committee was obtained, and informed consent was provided
before the start of the immunotherapy.
Assessment of extent of tumour resection before
vaccination
Complete resection was defined as the absence of any residual
tumour mass on early postoperative MRI or CT scan performed
with and without contrast within 72h after surgery. Any resection
leaving a measurable residual tumoral mass o1cm
3 and o10% of
the initial tumour volume was considered subtotal. All solid
residual tumour of a measurable size X1cm
3 or removal of o90%
of the tumour volume was classified as partial resection.
Tumour homogenate
Tumour tissue was immediately transported from the operation
room into the laboratory and snap-frozen in liquid N2 without
additives. For further preparation, the tissue was thawed and put
into NaCl 0.9% with 1% human serum albumin, and was
homogenised mechanically. Afterwards, six snap freeze/thaw
cycles were performed. The homogenate was filtered with a Falcon
filter (70mm). The amount of protein was measured using the
Coomassie blue staining method and spectrophotometry at 595nm
(Bradford, 1976). After irradiation (60Gy), the homogenate was
kept frozen in liquid nitrogen until use.
Preparation of autologous DC
In eight patients peripheral blood mononuclear cells (PBMC) were
isolated from fresh blood samples. DC were differentiated out of
the monocytes in the presence of 20ngml
 1 rIL-4 (Pepro Tech
Inc., Rocky Hill, NJ, USA) and 1000Uml
 1 rGM-CSF (Leuko-
max
s, Novartis) for 7 days as described (Sallusto and Lanzavec-
chia, 1994). In the other patients, PBMC were obtained from
leukapheresis, and kept frozen until use. For each vaccination, part
of the PBMC was thawed, and adherent cells were differentiated to
immature DC as described (Thurner et al, 1999). Immature DC
were loaded with 30–200mg of tumour proteins per million DC,
depending on the material available. For the loading procedure,
0.01% autologous plasma was used during the first 2h, 0.04% for
the next 4h, and finally 0.28% for the last 20h. At time of loading,
rTNF-a (Strathmann Biotec AG, Dengelsberg, Germany), rIL-1b
(Strathmann Biotec AG) and PGE2 (Prostin
s, Pharmacia) were
added in a final concentration of 120, 120 and 20mgml
 1
respectively. After 24h, mature loaded DC were resuspended in
PBS with 0.5% human serum albumin (HSA) at a concentration of
2–6 10
6ml
 1. The syringes contained 1–2 million mature DC.
Vaccination
Vaccination was performed by intradermal (i.d.) injection of 2–4
million DC per lymph node region in the upper third of the arms at
weeks 1, 3, and further with an interval of 4 weeks. The patients
were kept in the hospital for 2h after vaccination.
Skin tests
Delayed type hypersensitivity reaction (DTH) was tested after at
least two vaccinations. For this, 100ml tumour homogenate and
100ml control PBS/HSA were injected i.d. After 24, 48, and 72h,
redness and induration were assessed by an independent observer.
DTH reactions were judged as positive if the average perpendicular
measurement of the reaction exceeded 5mm.
Patient assessment
All patients were followed by clinical examination and MRI
scanning. In eight patients, methionine-PET imaging was per-
formed. Imaging studies were scheduled before each vaccine
except the second vaccine. Afterwards, clinical examination and
imaging studies were performed every 3–4 months.
RESULTS
Vaccines preparation and characterisation
The patients received 2–7 (median: 5) vaccines after surgery. The
details of the vaccinations for each patient are described in Table 2.
The median yield of DC from freshly isolated PBMC was 4.8 10
6
Table 1 Patient characteristics
Patient
number
Age
(year) Sex
Time of prior
events
Prior
histology
Prior
treatment
Time of last
relapse
Histology at
relapse
1 60 M 02-2000 GBM S, R, C 10-2000 GBM
2 11 F 02-1997 AA S, R, C 05-2001 PXA
05-1999 AA
3 17 F 01-1989 PA S, R 06-2001 GBM
03-1999 AA S, R, C
4 15 M 02-1998 GBM S, R, C 06-2001 GBM
5 34 F 07-2001 AA S, R 07-2001 GBM
6 53 M 02-2001 GBM S, R, C 12-2001 GBM
7 78 M 05-1999 GBM S, R, C 02-2002 GBM
8 62 F 08-2001 GBM S, R, C 04-2002 GBM
9 39 F 01-1995 ODG III S, R, C 05-2002 GBM
03-2000 ODG IV
10 30 M 09-1999 AA S, R, C 05-2002 GBM
11 15 F 12-1990 ALL C 06-2002 No vital tissue after tumour bleeding
10-2001 GBM S, R
12 62 F 4-9-2001 GBM S, R, C 09-2002 GBM
AA¼anaplastic astrocytoma; ALL¼acute lymphatic leukaemia; C¼chemotherapy; F¼female; GBM¼glioblastoma multiforme; III¼WHO grade 3r, IV¼WHO grade 4r;
M¼male; ODG¼oligodendroglioma; PA¼pilocytic astrocytoma; PXA¼malignant pleomorphic xanthoastrocytoma; R¼radiotherapy; S¼surgery.
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lper injection (range: 0.8–13 10
6; n¼37), which was significantly
(Mann–Whitney test: P¼0.0007) less than the median yield of DC
from leukapheresis PBMC (median 10, range: 3–18 10
6; n¼22).
The quality of the DC was controlled by the expression of HLA-DR,
CD80, CD86 and CD83 (Figure 1) (Thurner et al, 1999).
Therapy-induced clinical effects
The details of the therapy-induced clinical effects are given in
Table 3. The progression free survival (PFS) and overall survival
(OS) at 36 months for the total group was 17% (median
PFS¼3months; OS¼10.5months). In the six patients with
residual tumour load after surgery and prior to vaccination, one
stable disease (patient 1, Figure 2) and one partial response of a
metastatic lesion (patient 6, Figure 3) were observed based on the
volumetric analysis of the tumour. In the latter patient, the right
temporal lesion, displaying a high grade malignant metabolic
uptake ratio of 2.95 on methionine-PET, decreased in volume by
50% after the third vaccination (Figure 3). In two out of six
patients (patients 2 and 3) who had complete resection of their
tumour, continuous complete remission was observed at the
moment of writing the manuscript, with a follow-up of 36 and 35
months respectively. Patient 3 had a transient contrast enhance-
ment around the resection cavity after the fifth vaccine together
with a transient increase of metabolic activity around the resection
cavity, measured by methionine-PET (De Vleeschouwer et al,
Table 2 Vaccination data
Patient
number
Surgery prior to
vaccination Source of PBMC
Number of
vaccinations
Amount of cells injected
per vaccination ( 10
6) Skin test
1 Partial resection Leukapheresis 5 5/18/17/16/15 Not done
2 Total resection Leukapheresis 7 4/3/4/16/10/14/13  V2, +V6
3 Total resection Fresh blood 6 3/1/2/9/1/2 +V3
4 Total resection Leukapheresis 4 13/11/10/9  V3
5 Total resection Fresh blood 5 3/1.4/4.8/3/5 Not done
6 Total resection, second localisation Fresh blood 3 8/7/6 +V3
7 Subtotal resection Fresh blood 5 12/2/7/12/9 +V3
8 Partial resection Fresh blood 2 13/6 Not done
9 Subtotal resection Fresh blood 5 9/3/2.4/2.5/0.8  V3
10 Subtotal resection Fresh blood 5 4.8/2.1/1.4/5.5/6 +V3
11 Total resection (no vital tumour) Leukapheresis 6 15/8/6/4/4/4 Not done
12 Total resection Fresh blood 6 10/13/9/5/4.2/3 +V3
Vx¼vaccine number.
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Figure 1 Quality control of dendritic cells. Representative example obtained by FACS analysis, of the expression of surface markers on loaded mature
dendritic cells at the time of injection.
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l2004). Although the patient numbers were small, patient outcome
was not depending on the procedure of making DC or on the
amount of proteins to load DC or on the total amount of DC
injected. Overall, in four out of 12 patients (patients 1, 2, 3 and 6),
some evidence for tumour control due to immunotherapy was
observed, and in three of them (patient 1, 3 and 6) an objective
response was measured.
Immune response
In eight patients, a DTH skin test with crude autologous tumour
homogenate was performed, of which only two tests remained
negative at the time of third vaccination. In one patient, the skin
test at the time of the second vaccination was negative, but became
positive when the test was performed again at the time of the sixth
vaccination. In patient 1, the peritumoral oedema related to each
vaccination since the second vaccination was considered as
immune-mediated. Therefore, no additional skin test was
performed in parallel. Due to the small amount of tumour proteins
available in the other patients, the skin test could not be carried
out. No relation between positive skin test and response of the
tumour or survival of the patient could be found in this small
group of patients. There was also no trend in any direction that the
amount of proteins used to load DC or the amount of DC injected
had any effect on the induction of DTH reaction or on the clinical
outcome.
Toxicity
No severe adverse events were noted, except for one patient. This
patient suffered from peritumoral oedema that caused grade IV
(NCI common toxicity criteria) neurological deficits and lethargy
after vaccinations 2–5, but not after the first vaccination.
Remarkably, the period of oedema appeared 30h after V2, 4 days
after V3, and 9 days after V4, while the tumour volume calculated
according to the formula A B C/2 (A, B and C are the largest
diameters in axial, sagittal and coronal plane) remained stable.
These symptoms were successfully controlled within 48h by
administering steroids. The other 11 patients did not require
corticosteroids during the vaccination period.
In patient 3, a transient contrast enhancement was accompanied
by a transient history of more pronounced morning stiffness (De
Vleeschouwer et al, 2004). Further toxicities were grade II hemato-
toxicity in one blood sample (patients 5 and 6), nocturnal sweating
after the fourth vaccine (patient 9), and meningeal irritation after
the third vaccine (patient 10). In the latter patient, lumbar
puncture at that time revealed 8.4 white blood cells per ml with 83%
lymphocytes. The CSF was haemorrhagic, with proteins of
1511mgl
 1, glucose of 50mgdl
 1 and lactate of 2.92mmoll
 1.
Bacterial cultures and viral PCR tests remained negative. In the
other patients, no vaccine-related toxicity was observed.
Only patient 1 and patient 10 have been admitted into hospital
due to vaccine-related symptoms. All the other patients received
their treatment as outpatients. In patient 8, tumour progression
after the partial resection was so overwhelming that only two
Table 3 Clinical evolution and outcome
Patient
number
Clinical data during
vaccination Radiological evolution
Therapy-induced
clinical effect
Follow-up period
after surgery
(months)
Treatment after vaccination,
current status
1 Peritumoral oedema with
grade IV neurotoxicity,
responding to steroids
Peritumoral oedema from V2;
SD during 7–8 weeks, later PD
Yes 7 DOD at 05-2001
2 Nihil — Yes 36 CCR
3 Morning stiffness after V5 Transient contrast enhancement after V5Yes 35 CCR
4 Nihil Relapse after 3 months No 12 Surgery, chemotherapy; DOD at 07-2002
5 At moment of V3:
thrombocytes¼72000ml
 1
Relapse after 3 months No 23 Temozolomid; Ommaya reservoir and
repetitive punctions of cystic fluid;
DOD at 11-2003
6 Subdural hygroma after surgery,
anaemia after V3: Hb¼9gdl
 1
CCR of primary tumour;
progression and later on regression of
metastatic lesion
Yes 7 Abruption of further vaccination; w at 09-2002
7 Nihil PD after 2 months No 8 DOD at 10-2002
8 Nihil Immediate progression No 4 DOD at 08-2002
9 Night sweating after V4 PD after 2 months No 7 Chemotherapy; DOD at 12-2002
10 Meningismus after V3 PD after 4 months No 9 Chemotherapy; DOD at 02-2003
11 Nihil PD after 16 months No 17 DOD at 11-2003
12 Nihil Relapse after 3 months No 14 Chemotherapy; DOD at 11-2003
CCR¼continuous complete remission; DOD¼death of disease; Hb¼Haemoglobin; PD¼progressive disease; SD¼stable disease; Vx¼vaccine number.
Patient 1
0 25 50 75 100 125 150
0
100
200
Tumour volume (ml)
Oedema
Oedema
Vaccine
Partial resection
Day
Figure 2 Evolution of tumour volume and response in patient 1. Pre-
and postoperative time course of tumour volume (assessed on consecutive
MRI images), and of peritumoral oedema reaction (assessed by neurological
clinical examination and emergency CT). The time points of operation (day
0) and vaccines (days 31, 45, 65, 89, 129) are indicated.
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lvaccines could be administered because of the rapid decline of the
patient’s neurological status.
DISCUSSION
We summarised the observations on 12 patients with relapsed
malignant glioma who were vaccinated with autologous DC loaded
with autologous crude tumour homogenate after reoperation. In
25% of patients, we documented an objective clinical response.
The report illustrates that, in spite of considerable logistical and
technical difficulties, it is worthwhile to further develop the
approach of protein-loaded DC as therapy against malignant
glioma, even in the absence of known target antigens and for
tumours in immunologically privileged sites such as the brain.
An increasing number of clinical trials evaluate DC-based
vaccines in the therapy of cancer in adult (Jefford et al, 2001) and
in pediatric patients (Geiger et al, 2001). Specific peptides were
mostly used in DC vaccination strategies for melanoma, prostate
cancer or breast/ovarian cancer. Also for malignant brain tumour,
MHC class I-associated peptides have been eluted from cultured
autologous glioma cells, and a mixture of peptides was used to load
DC since no specific tumour antigenic targets are known (Yu et al,
2001). In other trials, tumour proteins instead of peptides have
been used to load DC (Hsu et al, 1996; Schott et al, 2000;
Geiger et al, 2001; Chang et al, 2002; Ho ¨ltl et al, 2002; Wheeler
et al, 2003; Yamanaka et al, 2003; De Vleeschouwer et al, 2004).
The use of proteins from autologous tumours instead of peptides is
now generally considered a valuable approach, certainly
when tumour-specific epitopes are not known (Curiel and Curiel,
2002).
The technical aspects of DC vaccination have recently been
reviewed (Schuler et al, 2003). Intradermal administration of
loaded mature DC seems to be preferable. Up to now, only
empirical DC schedules are used. Our observational study pointed
to some further practical issues according to feasibility. The size of
the tumour sample and the yield of tumour proteins available to
load DC were different for each patient. Based on laboratory data
on antigen-presenting capacity and quality of DC (manuscript
submitted), the range to load one million DC was kept between 30
and 200mg of tumour proteins. Similarly, the number of DC per
injection was different for each preparation and reflect an
unavoidable heterogeneity commonly encountered in such studies
(Geiger et al, 2001; Ho ¨ltl et al, 2002). The fact that some or our
patients had tumour control obtained after injection of lower
numbers of DC is remarkable.
As this is a feasibility study, it is important to stress that the only
selection of candidates for the adjuvant DC-based vaccination
therapy was the surgical operability: all patients in whom an
intended extensive tumour debulking was deemed feasible and safe
by the neurosurgeon were eligible. The actual fraction of patients
with a recurrent glioma, who possibly could benefit from this
adjuvant therapy in this stage, can only be estimated and probably
approaches 10%. Not a single included patient, however, dropped
out after surgery: only in patient 2 (partial resection), we stopped
after the second vaccination because of overwhelming tumour
progression with rapid decline of her neurological status.
Immune monitoring was performed with skin tests, when
enough tumour material was available. The DTH testing to antigen
is one clinical monitoring tool to indicate cellular immunity,
although it remains controversial whether or not DTH to
autologous tumour can be a reliable correlate of clinical responses
19-2-2002
Preoperative
26-2-2002
Postoperative
22-03-2002 10-4-2002 11-6-2002
Patient 6
V1 V2 V3
Figure 3 Continuous complete remission of reoperated tumour and partial response of second localisation in patient 6. MRI scan at time of pre- and
postoperative status (upper panel); and postoperative evolution on MRI scan during and after vaccination (lower panel). Tumour resection was performed at
25-2-2002. Vaccinations were given at 14-3-02, 28-3-02 and 25-4-02. After the third vaccination, tumour volume in the right temporal lobe decreased by
50%.
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l(Clay et al, 2001). DTH tests are commonly used if a mixture of
undefined tumour proteins is used as a source of antigen for the
DC (Geiger et al, 2001; Yamanaka et al, 2003). Additional immune
monitoring with Elispot should be implemented when future
patients are treated (Geiger et al, 2001; Chang et al, 2002;
Yamanaka et al, 2003).
The group of patients was heterogeneous, because we wanted to
assess general feasibility of tumour vaccination. Based on the
safety (patient 1) and efficacy (patients 2 and 3) data obtained,
(sub)total resection of the tumour should be the major inclusion
criteria for upcoming DC vaccination strategies. The induction of
serious and clinically important peritumoral oedema in our first
patient shows a potential and unacceptable vaccination-related
risk for patients with partially resected tumours. From an
immunological point of view, tumour-induced immune suppres-
sive mechanisms are limited when the tumour burden is lowered
(Holladay et al, 1994). In addition, steroids can generally be
weaned faster in case of (sub)total resection. Previous unpublished
studies of our group showed that sufficient numbers of high
quality DC cannot be obtained in glioma patients receiving
steroids shortly prior to blood sampling. In fact, our observations
illustrate in clinical practice that surgery-induced minimal residual
disease is a prerequisite for a clinically relevant efficacy of DC
vaccination (Smyth et al, 2001). Vaccination might induce better
survivals in younger patients, in whom complete resection of
malignant glioma can be reached more frequently. Moreover, the
cytogenetic entity of malignant glioma at younger age differs from
adult malignant glioma (Kraus et al, 2002) and might also be
responsible for different immunological targeting, besides the
differences in immune competence at younger age (Wheeler et al,
2003). To further implement these issues, the ongoing HGG-
IMMUNO-2003 trial of our group includes patients below the age
of 60 years with at least subtotal resection of the relapsed tumour.
The amount of tumour proteins available should be enough to be
able to provide at least five vaccines with at least 5 10
6 DC loaded
with at least 50mg tumour proteins per 10
6 DC. The clinical effects
will be evaluated by determining the PFS, OS and quality of life in a
larger series, and in comparison to a matched historical control
group. The immunological effects of DC vaccination in these
patients will be further elucidated including Elispot immune
monitoring.
After standard treatment for newly diagnosed malignant glioma,
patients with early relapse and at least subtotally resectable
tumours may particularly benefit from adjuvant immunotherapy.
DC immunotherapy appears promising as an approach to
successfully induce an antitumour immune response and long-
lasting tumour control. This may prolong survival of patients with
malignant brain tumours without compromising their quality of
life.
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